Neoadjuvant treatments in patients with high-risk resectable stage III/IV melanoma

References

• Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the American Joint Committee on cancer eighth edition cancer staging manual: melanoma staging: AJCC 8 th edition. CA Cancer J Clin. 2017 Nov;67(6):472–492.
   PubMed Web of Science ®Google Scholar
• Queirolo P, Spagnolo F. BRAF plus MEK-targeted drugs: a new standard of treatment for BRAF-mutant advanced melanoma. Cancer Metastasis Rev. 2017 Mar 1;36(1):35–42.
   PubMed Web of Science ®Google Scholar
• Queirolo P, Boutros A, Tanda E, et al. Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy. Semin Cancer Biol [Internet]. 2019 Aug 17; Available from: http://www.sciencedirect.com/science/article/pii/S1044579X19301956
   Web of Science ®Google Scholar
• Ives NJ, Suciu S, Eggermont AMM, et al. Adjuvant interferon-α for the treatment of high-risk melanoma: an individual patient data meta-analysis. Eur J Cancer. 2017 Sept;1(82):171–183.
   Google Scholar
• Eggermont AMM, Chiarion-Sileni V, Grob -J-J, et al. Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European organisation for research and treatment of cancer 18071 double-blind phase 3 randomised trial. Eur J Cancer. 2019 Sept 1;119:1–10.
   PubMed Web of Science ®Google Scholar
• Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017 Sept 10;377(19):1824–1835.
   PubMed Web of Science ®Google Scholar
• Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018 Apr 15;378(19):1789–1801.
   PubMed Web of Science ®Google Scholar
• Hauschild A, Dummer R, Schadendorf D, et al. Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600-mutant stage III melanoma. J Clin Oncol Off J Am Soc Clin Oncol. 2018 Oct 22;36(35):JCO1801219–JCO1801219.
   Web of Science ®Google Scholar
• Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014 Feb 13;370(7):599–609.
   PubMed Web of Science ®Google Scholar
• Bello DM, Faries MB. The Landmark Series: MSLT-1, MSLT-2 and DeCOG (management of lymph nodes). Ann Surg Oncol [Internet]. 2019 Sept 18. DOI:10.1245/s10434-019-07830-w
   Web of Science ®Google Scholar
• Faries MB, Thompson JF, Cochran AJ, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 2017 June 8;376(23):2211–2222.
   PubMed Web of Science ®Google Scholar
• Leiter U, Stadler R, Mauch C, et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2016 June;17(6):757–767.
   PubMed Web of Science ®Google Scholar
• Coit DG, Thompson JA, Albertini MR, et al. Cutaneous melanoma, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw JNCCN. 2019 Apr 1;17(4):367–402.
   PubMed Web of Science ®Google Scholar
• Garbe C, Amaral T, Peris K, et al. European consensus-based interdisciplinary guideline for melanoma. part 2: treatment – update 2019. Eur J Cancer. 2020 Feb 1;126:159–177.
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Borgognoni L, Botti G, et al. New paradigm for stage III melanoma: from surgery to adjuvant treatment. J Transl Med. 2019 Aug 14;17(1):266.
   PubMed Web of Science ®Google Scholar
• Eggermont AMM, Blank CU, Mandala M, et al. Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. Eur J Cancer. 2019 July 1;116:148–157.
   PubMed Web of Science ®Google Scholar
• Huang AC, Orlowski RJ, Xu X, et al. A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nat Med. 2019 Mar;25(3):454–461.
   PubMed Web of Science ®Google Scholar
• Korn EL, Liu P-Y, Lee SJ, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol. 2008 Feb 1;26(4):527–534.
   PubMed Web of Science ®Google Scholar
• Shah GD, Socci ND, Gold JS, et al. Phase II trial of neoadjuvant temozolomide in resectable melanoma patients. Ann Oncol Off J Eur Soc Med Oncol. 2010 Aug;21(8):1718–1722.
   PubMed Web of Science ®Google Scholar
• Khunger A, Buchwald ZS, Lowe M, et al. Neoadjuvant therapy of locally/regionally advanced melanoma. Ther Adv Med Oncol. 2019;11:1758835919866959.
   Web of Science ®Google Scholar
• Buzaid AC, Colome M, Bedikian A, et al. Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with local-regional metastases. Melanoma Res. 1998 Dec;8(6):549–556.
   PubMed Web of Science ®Google Scholar
• Gibbs P, Anderson C, Pearlman N, et al. A phase II study of neoadjuvant biochemotherapy for stage III melanoma. Cancer. 2002 Jan 15;94(2):470–476.
   PubMed Web of Science ®Google Scholar
• Lewis KD, Robinson WA, McCarter M, et al. Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma. J Clin Oncol. 2006 July 1;24(19):3157–3163.
   PubMed Web of Science ®Google Scholar
• Spagnolo F, Boutros A, Tanda E, et al. The adjuvant treatment revolution for high-risk melanoma patients. Semin Cancer Biol. 2019 Dec;59:283–289.
   PubMed Web of Science ®Google Scholar
• Schadendorf D, Hodi FS, Robert C, et al. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol Off J Am Soc Clin Oncol. 2015 June 10;33(17):1889–1894.
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019 Sept 27;381(16):1535–1546.
   PubMed Web of Science ®Google Scholar
• Robert C, Ribas A, Schachter J, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 2019 Sept 1;20(9):1239–1251.
   PubMed Web of Science ®Google Scholar
• Moschos SJ, Edington HD, Land SR, et al. Neoadjuvant treatment of regional stage IIIB Melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol [Internet]. 2016 Sept 21 [cited 2019 Dec 7].DOI:10.1200/JCO.2005.05.2498
   Google Scholar
• Tarhini AA, Edington H, Butterfield LH, et al. Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. chatenoud L, editor. PLoS ONE. 2014 Feb 3;9(2):e87705.
   PubMed Web of Science ®Google Scholar
• Tarhini A, Lin Y, Lin H, et al. Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire. J Immunother Cancer. 2018 Dec;6(1):112.
   PubMed Web of Science ®Google Scholar
• Tarhini AA, Lin Y, Drabick JJ, et al. Neoadjuvant combination immunotherapy with pembrolizumab and high dose IFN-α2b in locally/regionally advanced melanoma. J Clin Oncol. 2018 Feb 10;36(5_suppl):181.
   Web of Science ®Google Scholar
• Blank CU, Rozeman EA, Fanchi LF, et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat Med. 2018 Nov;24(11):1655–1661.
   PubMed Web of Science ®Google Scholar
• Rozeman EA, Menzies AM, van Akkooi ACJ, et al. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Lancet Oncol. 2019 July;20(7):948–960.'
   PubMed Web of Science ®Google Scholar
• Amaria RN, Reddy SM, Tawbi HA, et al. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018 Nov 1;24(11):1649–1654.
   PubMed Web of Science ®Google Scholar
• Sanlorenzo M, Vujic I, Carnevale-Schianca F, et al. Role of interferon in melanoma: old hopes and new perspectives. Expert Opin Biol Ther. 2017 Apr 3;17(4):475–483.
   PubMed Web of Science ®Google Scholar
• Balch CM, Gershenwald JE, Soong S-J, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol Off J Am Soc Clin Oncol. 2009 Nov 16. 2009 Dec 20;27;(36)6199–6206.
   PubMed Web of Science ®Google Scholar
• Blank CU, Versluis JM, Reijers ILM, et al. 3-year relapse-free survival (RFS), overall survival (OS) and long-term toxicity of (neo)adjuvant ipilimumab (IPI) + nivolumab (NIVO) in macroscopic stage III melanoma (OpACIN trial). Ann Oncol. 2019 Oct 1;30:v535.
   Web of Science ®Google Scholar
• Rozeman EA, Menzies AM, Krijgsman O, et al. 18-months relapse-free survival (RFS) and biomarker analyses of OpACIN-neo: a study to identify the optimal dosing schedule of neoadjuvant (neoadj) ipilimumab (IPI) + nivolumab (NIVO) in stage III melanoma. Ann Oncol. 2019 Oct 1;30:v910.
   Web of Science ®Google Scholar
• Ascierto PA, Dummer R, Gogas HJ, et al. Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600–mutant melanoma. Eur J Cancer. 2020 Feb 1;126:33–44.
   PubMed Web of Science ®Google Scholar
• Robert C, Grob JJ, Stroyakovskiy D, et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med. 2019 June 4;381(7):626–636.
   PubMed Web of Science ®Google Scholar
• Ascierto PA, McArthur GA, Dréno B, et al. Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016 Sept 1;17(9):1248–1260.
   PubMed Web of Science ®Google Scholar
• Amaria RN, Prieto PA, Tetzlaff MT, et al. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol. 2018 Feb;19(2):181–193.
   PubMed Web of Science ®Google Scholar
• Long GV, Saw RPM, Lo S, et al. Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial. Lancet Oncol. 2019 July;20(7):961–971.
   PubMed Web of Science ®Google Scholar
• Eroglu Z, Eatrides J, Naqvi SMH, et al. Neoadjuvant BRAF-targeted therapy in regionally advanced and oligometastatic melanoma. Pigment Cell Melanoma Res. 2020 Jan;33(1):86–95.
   PubMed Web of Science ®Google Scholar
• Blankenstein S, Rohaan M, Klop M, et al. High response rates after neoadjuvant cytoreductive treatment with BRAF/MEK inhibition of prior unresectable regionally advanced melanoma, REDUCTOR trial. Eur J Surg Oncol. 2019 Feb;45(2):e6.
   Google Scholar
• Weide B, Neri D, Elia G. Intralesional treatment of metastatic melanoma: a review of therapeutic options. Cancer Immunol Immunother. 2017 May;66(5):647–656.
   PubMed Web of Science ®Google Scholar
• Andtbacka RHI, Kaufman HL, Collichio F, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015 June 22;33(25):2780–2788.
   PubMed Web of Science ®Google Scholar
• Andtbacka RHI, Dummer R, Gyorki DE, et al. Interim analysis of a randomized, open-label phase 2 study of talimogene laherparepvec (T-VEC) neoadjuvant treatment (neotx) plus surgery (surgx) vs surgx for resectable stage IIIB-IVM1a melanoma (MEL). J Clin Oncol. 2018 May 20;36(15_suppl):9508.
   Web of Science ®Google Scholar
• Dummer R, Gyorki DE, Hyngstrom J, et al. LBA66 - Primary 2-year (yr) results of a phase II, multicenter, randomized, open-label trial of efficacy and safety for talimogene laherparepvec (T-VEC) neoadjuvant (neo) treatment (tx) plus surgery (surg) vs surg in patients (pts) with resectable stage IIIB-IVM1a melanoma. Abstr book 44th ESMO Congr ESMO 2019 27 Sept – 1 Oct 2019. Barc Spain. 2019 Oct 1;30:v903.
   Google Scholar
• Danielli R, Patuzzo R, Di Giacomo AM, et al. Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study. Cancer Immunol Immunother. 2015 Aug;64(8):999–1009.
   PubMed Web of Science ®Google Scholar
• Menzies AM, Rozeman EA, Amaria RN, et al. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the international neoadjuvant melanoma consortium (INMC). J Clin Oncol. 2019 May 20;37(15_suppl):9503.
   Web of Science ®Google Scholar
• Amaria RN, Menzies AM, Burton EM, et al. Neoadjuvant systemic therapy in melanoma: recommendations of the international neoadjuvant melanoma consortium. Lancet Oncol. 2019 July 1;20(7):e378–89.
   PubMed Web of Science ®Google Scholar
• Li J, Chen S, Chen C, et al. Pathological complete response as a surrogate for relapse-free survival in patients with triple negative breast cancer after neoadjuvant chemotherapy. Oncotarget [Internet]. 2017 Mar 14 [cited 2020 Jan 5];8(11). Available from: http://www.oncotarget.com/fulltext/9369
   Google Scholar
• Hellmann MD, Chaft JE, William WN, et al. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol. 2014 Jan;15(1):e42–50.
   PubMed Web of Science ®Google Scholar
• Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014 July;384(9938):164–172.
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Ferrucci PF, Fisher R, et al. Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma. Nat Med. 2019 June 1;25(6):941–946.
   PubMed Web of Science ®Google Scholar